UpStream Bio Inc. UPB 深 滬
等待開盤 08-15 09:30:00 美东时间
18.83
+0.270
+1.45%
華盛通- 最 高18.95
- 今 開18.43
- 成交量 31.64万股
- 最 低 16.80
- 昨 收 18.56
- 總市值 10.13亿
- 52周最高 29.4599
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 5.14
- 委 比 -60.00%
- 總股本 5379.37万
- 歷史最高 29.4599
- 量 比 0.67
- 振 幅 11.58%
- 歷史最低 5.14
- 每 手 1
- 風險率 6.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Claros Mortgage Trust outlines $2B+ loan resolution trajectory while advancing REO strategies
Earnings Call Insights: Claros Mortgage Trust (CMTG) Q2 2025 Management View Richard Jay Mack, CEO, stated that while "the elevated rate environment remains a headwind for commercial real estate, we'r...
08-08 17:33
Upstream Bio, Inc. Reports Increased R&D Investments
Upstream Bio, Inc. ( ($UPB) ) has released its Q2 earnings. Here is a breakdown...
08-07 14:51
Upstream Bio, Inc. reports Q2 results
Upstream Bio, Inc. press release (NASDAQ:UPB): Q2 Revenue of $0.9M. Net loss was $40.0 million for the quarter ended June 30, 2025, compared to a net loss of $14.7 million for the same period in 2024....
08-06 19:48
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio reported Q2 2025 financial results and highlighted recent business milestones. The company advanced Verekitug, a monoclonal antibody targeting TSLP receptor, in Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Enrollment was completed in the severe asthma trial in June 2025, with top-line data expected in Q1 2026. The first patient was dosed in the ...
08-06 11:00
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on ...
07-28 22:29
Upstream Bio Doses First COPD Patient in Phase 2 Trial for Anti-Inflammatory Drug Verekitug
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the first patient has been dosed in
07-08 19:02
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
Upstream Bio, Inc. has initiated a Phase 2 clinical trial, VENTURE (NCT06981078), evaluating verekitug, a TSLP receptor antagonist, in patients with moderate-to-severe COPD. The trial will assess its efficacy and safety when administered every 12 or 24 weeks. Verekitug is the only known biologic targeting the TSLP receptor, with potential benefits for COPD treatment. The primary endpoint is the annualized rate of moderate or severe COPD exacerbat...
07-08 11:00
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
Upstream Bio, Inc. announced pharmacology modeling data at the EAACI Congress highlighting verekitug's superior potency compared to tezepelumab by targeting the TSLP receptor. Verekitug, a monoclonal antibody, inhibits TSLP signaling, potentially offering broad therapeutic benefits across inflammatory diseases like severe asthma, COPD, and CRSwNP. Data showed complete inhibition of the TSLP/TSLPR complex and greater FeNO reduction with verekitug,...
06-15 11:45
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
Upstream Bio will present data on verekitug, a TSLP receptor antagonist, at the EAACI Congress 2025, showcasing its potential for greater potency compared to ligand-targeting approaches. Verekitug, the only TSLP receptor-targeting monoclonal antibody in clinical development, is being tested in Phase 2 trials for severe asthma and chronic rhinosinusitis, with an upcoming trial for COPD. The presentation will highlight translational pharmacology mo...
06-05 11:00
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Upstream Bio, Inc., a clinical-stage biotechnology company developing treatments for inflammatory diseases, announced that its CEO, Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The webcast will be available on the company's website, with a replay posted afterward. Upstream Bio is advancing verekitug, a monoclonal antibody targeting the receptor for thymic ...
06-04 11:00
